Copenhagen, 2015-11-16 17:38 CET (GLOBE NEWSWIRE) -- 16 November 2015 – Pursuant to the Danish Securities Trading Act, section 28a, Zealand must disclose information on transactions with the company’s shares and related securities by executives and persons/companies closely related to them. With reference to the above, Zealand announces it has received information on the following transactions for disclosure: Name: Christian Thorkildsen ---------------------------------------------------------------- Reason: Employee elected member of the Board of Directors ---------------------------------------------------------------- Issuer: Zealand Pharma A/S ---------------------------------------------------------------- Designation: Shares ---------------------------------------------------------------- ISIN Code: DK0060257814 ---------------------------------------------------------------- Transaction: Exercise of warrants ---------------------------------------------------------------- Trading Date: 13 November 2015 ---------------------------------------------------------------- Market: Nasdaq Copenhagen ---------------------------------------------------------------- Number: 27,000 ---------------------------------------------------------------- Price: DKK 77.00 ---------------------------------------------------------------- Total value: DKK 2,079,000.00 ---------------------------------------------------------------- Name: Helle Størum ---------------------------------------------------------------- Reason: Employee elected member of the Board of Directors ---------------------------------------------------------------- Issuer: Zealand Pharma A/S ---------------------------------------------------------------- Designation: Shares ---------------------------------------------------------------- ISIN Code: DK0060257814 ---------------------------------------------------------------- Transaction: Exercise of warrants ---------------------------------------------------------------- Trading Date: 13 November 2015 ---------------------------------------------------------------- Market: Nasdaq Copenhagen ---------------------------------------------------------------- Number: 7,500 ---------------------------------------------------------------- Price: DKK 77.00 ---------------------------------------------------------------- Total value: DKK 577,500.00 ---------------------------------------------------------------- Name: Jens Peter Stenvang ---------------------------------------------------------------- Reason: Employee elected member of the Board of Directors ---------------------------------------------------------------- Issuer: Zealand Pharma A/S ---------------------------------------------------------------- Designation: Shares ---------------------------------------------------------------- ISIN Code: DK0060257814 ---------------------------------------------------------------- Transaction: Exercise of warrants ---------------------------------------------------------------- Trading Date: 13 November 2015 ---------------------------------------------------------------- Market: Nasdaq Copenhagen ---------------------------------------------------------------- Number: 5,000 ---------------------------------------------------------------- Price: DKK 77.00 ---------------------------------------------------------------- Total value: DKK 385,000.00 ---------------------------------------------------------------- ????? For further information, please contact: Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications Tel: +45 50 60 36 89, email: hlh@zealandpharma.com About Zealand Pharma Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim. Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia® by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus®) which is on track for regulatory submission in the US in Q4 2015 and in the European Union in Q1 2016. The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics. The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www,zealandpharma.com or follow us on Twitter @ZealandPharma